Sensei biotherapeutics reports third quarter 2023 financial results and recent business highlights

- sns-101 initial phase 1 clinical data presented at sitc demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported -

SNSE Ratings Summary

SNSE Quant Ranking